Proof-of-Concept Trial for X-Linked Chronic Granulomatous Disease Treatment Shows Promise
According to a story from Markets Insider, the biopharmaceutical company Orchard Therapeutics recently announced the presentation of proof-of-concept data in regards to their investigational drug candidate OTL-102. This experimental therapy…